List of Tables 6
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Metastatic Breast Cancer Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Metastatic Breast Cancer 14
Metastatic Breast Cancer Therapeutics under Development by Companies 16
Metastatic Breast Cancer Therapeutics under Investigation by
Universities/Institutes 22
Late Stage Products 37
Comparative Analysis 37
Mid Clinical Stage Products 38
Comparative Analysis 38
Early Clinical Stage Products 39
Comparative Analysis 39
Discovery and Pre-Clinical Stage Products 40
Comparative Analysis 40
Metastatic Breast Cancer Therapeutics Products under Development by Companies
41
Metastatic Breast Cancer Therapeutics Products under Investigation by
Universities/Institutes 51
Companies Involved in Metastatic Breast Cancer Therapeutics Development 82
Bristol-Myers Squibb Company 82
Boehringer Ingelheim GmbH 83
F. Hoffmann-La Roche Ltd. 84
Kyowa Hakko Kirin Co., Ltd. 85
Abbott Laboratories 86
Biogen Idec Inc. 87
Amgen Inc. 88
Sanofi-Aventis 89
Adherex Technologies Inc. 90
AstraZeneca PLC 91
Eli Lilly and Company 92
GlaxoSmithKline plc 93
Genentech, Inc. 94
Nektar Therapeutics 95
Daiichi Sankyo Company, Ltd 96
Infinity Pharmaceuticals, Inc. 97
ZIOPHARM Oncology, Inc. 98
Millennium Pharmaceuticals, Inc. 99
Novartis AG 100
ImClone Systems Incorporated 101
Astellas Pharma Inc. 102
Eisai Co., Ltd. 103
Genta Incorporated 104
Nippon Kayaku Co., Ltd. 105
Pfizer Inc. 106
Taiho Pharmaceutical Co., Ltd. 107
Teva Pharmaceutical Industries Limited 108
Cell Therapeutics, Inc. 109
Enzon Pharmaceuticals, Inc. 110
Celgene Corporation 111
Bayer AG 112
Incyte Corporation 113
Geron Corporation 114
Merck KGaA 115
EntreMed, Inc. 116
Celldex Therapeutics, Inc. 117
Cougar Biotechnology, Inc. 118
Peregrine Pharmaceuticals, Inc. 119
Allos Therapeutics, Inc 120
Bionovo, Inc. 121
Cytokinetics, Inc 122
Telik, Inc. 123
Array BioPharma Inc. 124
Natco Pharma Limited 125
Piramal Life Sciences Limited 126
Wilex AG 127
TRION Pharma GmbH 128
BioNumerik Pharmaceuticals, Inc. 129
Cytheris SA 130
Quantum Immunologics, Inc. 131
PTC Therapeutics, Inc. 132
Immutep S.A. 133
Syndax Pharmaceuticals, Inc. 134
BiPar Sciences, Inc. 135
NewLink Genetics Corporation 136
Sopherion Therapeutics, LLC 137
AVEO Pharmaceuticals, Inc. 138
TRACON Pharmaceuticals, Inc. 139
Merus B.V. 140
Aragon Pharmaceuticals, Inc. 141
Oncozyme Pharma Inc. 142
Metastatic Breast Cancer Therapeutics Assessment 143
Assessment by Monotherapy Products 143
Assessment by Combination Products 144
Assessment by Route of Administration 145
Assessment by Molecule Type 148
Drug Profiles 151
Halaven - Drug Profile 151
SNDX 275 - Drug Profile 152
RG3502 - Drug Profile 154
Pertuzumab - Drug Profile 155
NKTR-102 - Drug Profile 156
Tavocept - Drug Profile 158
Avastin - Drug Profile 160
Afinitor - Drug Profile 162
BSI-201 - Drug Profile 164
IMC-1121B - Drug Profile 166
Herceptin + Radiation Therapy - Drug Profile 168
Anastrozole + Fulvestrant - Drug Profile 169
Herceptin + Navelbine - Drug Profile 170
FEC Chemotherapy + Docetaxel - Drug Profile 171
FEC Chemotherapy + DG Chemotherapy - Drug Profile 173
Fulvestrant. - Drug Profile 175
Fulvestrant + Exemestane + Anastrozole + Letrozole - Drug Profile 176
Fulvestrant + Lapatinib - Drug Profile 178
Faslodex + Arimidex - Drug Profile 180
Faslodex - Drug Profile 182
Exemestane - Drug Profile 183
Taxol - Drug Profile 185
Gemcitabine + Vinorelbine - Drug Profile 187
Capecitabine - Drug Profile 188
Bevacizumab + Paclitaxel - Drug Profile 189
Bevacizumab + Paclitaxel Albumin-Stabilized Nanoparticle Formulation - Drug
Profile 190
Bevacizumab + Ixabepilone - Drug Profile 191
Bevacizumab + Capecitabine - Drug Profile 192
Capecitabine - Drug Profile 193
Vinorelbine + Trastuzumab - Drug Profile 194
Marimastat - Drug Profile 196
Carboplatin + Paclitaxel + Trastuzumab + Bevacizumab - Drug Profile 197
Imatinib + Vinorelbine - Drug Profile 199
Afinitor + Exemestane - Drug Profile 200
Everolimus + Trastuzumab + Vinorelbine - Drug Profile 201
Tykerb + Paclitaxel - Drug Profile 203
BSI-201 + Gemcitabine + Carboplatin - Drug Profile 204
Docetaxel + Vitamin D2 - Drug Profile 206
Herceptin + Taxol - Drug Profile 207
Paclitaxel + Trastuzumab + GW572016 - Drug Profile 208
Avastin + Xeloda - Drug Profile 210
Irinotecan + 5-Fluorouracil + Leucovorin + Bevacizumab - Drug Profile 212
Avastin + Herceptin + Docetaxel - Drug Profile 214
Herceptin + Avastin - Drug Profile 216
Pertuzumab + Herceptin + Docetaxel - Drug Profile 217
Pertuzumab + Herceptin - Drug Profile 219
Avastin + Taxane - Drug Profile 221
Zoledronic Acid - Drug Profile 223
Herceptin - Drug Profile 224
Bevacizumab + Letrozole - Drug Profile 225
Docetaxel + Gemcitabine - Drug Profile 226
Aromasin + Celebrex - Drug Profile 227
Adiramycin + Cyclophosphamide + Docetaxel - Drug Profile 228
Bevacizumab + Paclitaxel - Drug Profile 229
Tamoxifen - Drug Profile 230
Taxotere + Epirubicin - Drug Profile 231
Navelbine + Taxotere - Drug Profile 232
Paclitaxel - Drug Profile 233
Epirubicin + Cyclophosphamide + 5-Fuorouracil - Drug Profile 234
Myocet + Taxol + Herceptin - Drug Profile 236
Trastuzumab-DM1 + Pertuzumab - Drug Profile 237
Theratope Vaccine + Detox - Drug Profile 239
Paclitaxel/Docetaxel + Lapatinib - Drug Profile 240
Lapatinib + Trastuzumab + Letrozole - Drug Profile 242
Docetaxel - Drug Profile 244
TS-1 - Drug Profile 245
Eribulin Mesylate - Drug Profile 246
IMC-1121B + Docetaxel - Drug Profile 247
Lapatinib + Trastuzumab + Anastrozole - Drug Profile 249
Lapatinib + Trastuzumab + Exemestane - Drug Profile 251
S-1 - Drug Profile 253
Doxorubicin + Docetaxel - Drug Profile 254
Doxorubicin + Paclitaxel - Drug Profile 255
Epirubicin + Cyclophosphamide - Drug Profile 256
Epirubicin + Docetaxel - Drug Profile 257
Epirubicin Hydrochloride + Paclitaxel - Drug Profile 258
Filgrastim + Carmustine + Cisplatin + Cyclophosphamide + Etoposide + Thiotepa +
Peripheral Blood Stem Cell Transplantation - Drug Profile 259
Cyclophosphamide + Epirubicin - Drug Profile 261
5-Fluorouracil + Leucovorin + Adriamycin + Cytoxan + Granulocyte-Macrophage
Colony-Stimulating Factor - Drug Profile 263
Docetaxel + Epirubicin + Cyclophosphamide + 5-Fluoruracil + Granulocyte-Colony
Stimulating Growth Factor - Drug Profile 265
Docetaxel + Epirubicin + Cyclophosphamide + 5-Fluoruracil + Trastuzumab +
Granulocyte-Colony Stimulating Growth Factor - Drug Profile 268
Filgrastim + Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil +
Thiotepa - Drug Profile 271
Bevacizumab + Capecitabine + Cyclophosphamide + Paclitaxel - Drug Profile 273
Capecitabine - Drug Profile 276
Aromasin + Entinostat - Drug Profile 277
Avastin + Docetaxel - Drug Profile 278
RAD001 + Trastuzumab + Paclitaxel - Drug Profile 280
Docetaxel + Pertuzumab + Trastuzumab - Drug Profile 282
Bevacizumab + Exemestane - Drug Profile 284
Bevacizumab + Fulvestrant - Drug Profile 285
Gemcitabine + Docetaxel - Drug Profile 286
Capecitabine + Docetaxel - Drug Profile 288
Avastin + Standard Chemotherapy - Drug Profile 290
Bevacizumab + Docetaxel - Drug Profile 292
Metastatic Breast Cancer Therapeutics Drug Profile Updates 293
Metastatic Breast Cancer Therapeutics Discontinued Products 311
Metastatic Breast Cancer Therapeutics - Dormant Products 317
Metastatic Breast Cancer Product Development Milestones 336
Featured News & Press Releases 336
Appendix 346
Methodology 346
Expert Panel Validation 347
Contact Us 347
Disclaimer 347
List of Tables
Number of Products Under Development for Metastatic Breast Cancer, H1 2012 20
Products under Development for Metastatic Breast Cancer Comparative Analysis,
H1 2012 21
Number of Products under Development by Companies, H1 2012 23
Number of Products under Development by Companies, H1 2012 (Contd..1) 24
Number of Products under Development by Companies, H1 2012 (Contd..2) 25
Number of Products under Development by Companies, H1 2012 (Contd..3) 26
Number of Products under Development by Companies, H1 2012 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2012 29
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..1) 30
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..2) 31
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..3) 32
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..4) 33
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..5) 34
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..6) 35
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..7) 36
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..8) 37
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..9) 38
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..10) 39
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..11) 40
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..12) 41
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..13) 42
Comparative Analysis by Late Stage Development, H1 2012 43
Comparative Analysis by Mid Clinical Stage Development, H1 2012 44
Comparative Analysis by Early Clinical Stage Development, H1 2012 45
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 46
Products under Development by Companies, H1 2012 47
Products under Development by Companies, H1 2012 (Contd..1) 48
Products under Development by Companies, H1 2012 (Contd..2) 49
Products under Development by Companies, H1 2012 (Contd..3) 50
Products under Development by Companies, H1 2012 (Contd..4) 51
Products under Development by Companies, H1 2012 (Contd..5) 52
Products under Development by Companies, H1 2012 (Contd..6) 53
Products under Development by Companies, H1 2012 (Contd..7) 54
Products under Development by Companies, H1 2012 (Contd..8) 55
Products under Development by Companies, H1 2012 (Contd..9) 56
Products under Investigation by Universities/Institutes, H1 2012 57
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 58
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 59
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 60
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 61
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 62
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 63
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 64
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 65
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 66
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 67
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 68
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 69
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 70
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 71
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 72
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 73
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 74
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 75
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 76
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 77
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 78
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 79
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 80
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 81
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 82
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 83
Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 84
Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 85
Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 86
Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 87
Bristol-Myers Squibb Company, H1 2012 88
Boehringer Ingelheim GmbH, H1 2012 89
F. Hoffmann-La Roche Ltd., H1 2012 90
Kyowa Hakko Kirin Co., Ltd., H1 2012 91
Abbott Laboratories, H1 2012 92
Biogen Idec Inc., H1 2012 93
Amgen Inc., H1 2012 94
Sanofi-Aventis, H1 2012 95
Adherex Technologies Inc., H1 2012 96
AstraZeneca PLC, H1 2012 97
Eli Lilly and Company, H1 2012 98
GlaxoSmithKline plc, H1 2012 99
Genentech, Inc., H1 2012 100
Nektar Therapeutics, H1 2012 101
Daiichi Sankyo Company, Ltd, H1 2012 102
Infinity Pharmaceuticals, Inc., H1 2012 103
ZIOPHARM Oncology, Inc., H1 2012 104
Millennium Pharmaceuticals, Inc., H1 2012 105
Novartis AG, H1 2012 106
ImClone Systems Incorporated, H1 2012 107
Astellas Pharma Inc., H1 2012 108
Eisai Co., Ltd., H1 2012 109
Genta Incorporated, H1 2012 110
Nippon Kayaku Co., Ltd., H1 2012 111
Pfizer Inc., H1 2012 112
Taiho Pharmaceutical Co., Ltd., H1 2012 113
Teva Pharmaceutical Industries Limited, H1 2012 114
Cell Therapeutics, Inc., H1 2012 115
Enzon Pharmaceuticals, Inc., H1 2012 116
Celgene Corporation, H1 2012 117
Bayer AG, H1 2012 118
Incyte Corporation, H1 2012 119
Geron Corporation, H1 2012 120
Merck KGaA, H1 2012 121
EntreMed, Inc., H1 2012 122
Celldex Therapeutics, Inc., H1 2012 123
Cougar Biotechnology, Inc., H1 2012 124
Peregrine Pharmaceuticals, Inc., H1 2012 125
Allos Therapeutics, Inc, H1 2012 126
Bionovo, Inc., H1 2012 127
Cytokinetics, Inc, H1 2012 128
Telik, Inc., H1 2012 129
Array BioPharma Inc., H1 2012 130
Natco Pharma Limited, H1 2012 131
Piramal Life Sciences Limited, H1 2012 132
Wilex AG, H1 2012 133
TRION Pharma GmbH, H1 2012 134
BioNumerik Pharmaceuticals, Inc., H1 2012 135
Cytheris SA, H1 2012 136
Quantum Immunologics, Inc., H1 2012 137
PTC Therapeutics, Inc., H1 2012 138
Immutep S.A., H1 2012 139
Syndax Pharmaceuticals, Inc., H1 2012 140
BiPar Sciences, Inc., H1 2012 141
NewLink Genetics Corporation, H1 2012 142
Sopherion Therapeutics, LLC, H1 2012 143
AVEO Pharmaceuticals, Inc., H1 2012 144
TRACON Pharmaceuticals, Inc., H1 2012 145
Merus B.V., H1 2012 146
Aragon Pharmaceuticals, Inc., H1 2012 147
Oncozyme Pharma Inc., H1 2012 148
Assessment by Monotherapy Products, H1 2012 149
Assessment by Combination Products, H1 2012 150
Assessment by Stage and Route of Administration, H1 2012 153
Assessment by Molecule Type, H1 2012 156
Metastatic Breast Cancer Therapeutics Drug Profile Updates 299
Metastatic Breast Cancer Therapeutics Discontinued Products 317
Metastatic Breast Cancer Therapeutics Discontinued Products (Contd..1) 318
Metastatic Breast Cancer Therapeutics Discontinued Products (Contd..2) 319
Metastatic Breast Cancer Therapeutics Discontinued Products (Contd..3) 320
Metastatic Breast Cancer Therapeutics Discontinued Products (Contd..4) 321
Metastatic Breast Cancer Therapeutics Discontinued Products (Contd..5) 322
Metastatic Breast Cancer Therapeutics Dormant Products 323
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..1) 324
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..2) 325
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..3) 326
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..4) 327
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..5) 328
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..6) 329
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..7) 330
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..8) 331
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..9) 332
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..10) 333
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..11) 334
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..12) 335
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..13) 336
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..14) 337
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..15) 338
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..16) 339
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..17) 340
Metastatic Breast Cancer Therapeutics Dormant Products (Contd..18) 341
List of Figures
Number of Products under Development for Metastatic Breast Cancer, H1 2012 20
Products under Development for Metastatic Breast Cancer Comparative Analysis,
H1 2012 21
Products under Development by Companies, H1 2012 22
Products under Investigation by Universities/Institutes, H1 2012 28
Late Stage Products, H1 2012 43
Mid Clinical Stage Products, H1 2012 44
Early Clinical Stage Products, H1 2012 45
Discovery and Pre-Clinical Stage Products, H1 2012 46
Assessment by Monotherapy Products, H1 2012 149
Assessment by Combination Products, H1 2012 150
Assessment by Route of Administration, H1 2012 151
Assessment by Stage and Route of Administration, H1 2012 152
Assessment by Molecule Type, H1 2012 154
Assessment by Stage and Molecule Type, H1 2012 155
|
